Enhanced In Vitro Magnetic Cell Targeting of Doxorubicin-Loaded Magnetic Liposomes for Localized Cancer Therapy.
magnetic drug targeting
magnetic liposomes
nanomedicine
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
23 Oct 2020
23 Oct 2020
Historique:
received:
25
09
2020
revised:
18
10
2020
accepted:
20
10
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
30
10
2020
Statut:
epublish
Résumé
The lack of efficient targeting strategies poses significant limitations on the effectiveness of chemotherapeutic treatments. This issue also affects drug-loaded nanocarriers, reducing nanoparticles cancer cell uptake. We report on the fabrication and in vitro characterization of doxorubicin-loaded magnetic liposomes for localized treatment of liver malignancies. Colloidal stability, superparamagnetic behavior and efficient drug loading of our formulation were demonstrated. The application of an external magnetic field guaranteed enhanced nanocarriers cell uptake under cell medium flow in correspondence of a specific area, as we reported through in vitro investigation. A numerical model was used to validate experimental data of magnetic targeting, proving the possibility of accurately describing the targeting strategy and predict liposomes accumulation under different environmental conditions. Finally, in vitro studies on HepG2 cancer cells confirmed the cytotoxicity of drug-loaded magnetic liposomes, with cell viability reduction of about 50% and 80% after 24 h and 72 h of incubation, respectively. Conversely, plain nanocarriers showed no anti-proliferative effects, confirming the formulation safety. Overall, these results demonstrated significant targeting efficiency and anticancer activity of our nanocarriers and superparamagnetic nanoparticles entrapment could envision the theranostic potential of the formulation. The proposed magnetic targeting study could represent a valid tool for pre-clinical investigation regarding the effectiveness of magnetic drug targeting.
Identifiants
pubmed: 33114052
pii: nano10112104
doi: 10.3390/nano10112104
pmc: PMC7690690
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nanomedicine (Lond). 2019 Mar;14(6):727-752
pubmed: 30574827
Adv Mater. 2017 Apr;29(14):
pubmed: 28234430
Adv Drug Deliv Rev. 2018 May;130:3-11
pubmed: 29778902
Int J Pharm. 2006 Jan 3;307(1):93-102
pubmed: 16303268
Nanotechnology. 2019 Aug 2;30(31):315101
pubmed: 30991371
Nanoscale. 2018 Dec 20;11(1):72-88
pubmed: 30357214
J Clin Oncol. 2009 Jun 20;27(18):3027-35
pubmed: 19470923
Cancer Res. 1994 Feb 15;54(4):987-92
pubmed: 8313389
J Vasc Interv Radiol. 2013 Mar;24(3):307-15
pubmed: 23375519
Nanomedicine. 2011 Dec;7(6):797-805
pubmed: 21419872
Clin Pharmacokinet. 2003;42(5):419-36
pubmed: 12739982
J Surg Res. 2001 Feb;95(2):200-6
pubmed: 11162046
Ann Biomed Eng. 2005 Jul;33(7):920-8
pubmed: 16060532
Nat Nanotechnol. 2007 Dec;2(12):751-60
pubmed: 18654426
ACS Appl Mater Interfaces. 2018 Jan 31;10(4):3229-3240
pubmed: 29313660
Invest Ophthalmol Vis Sci. 1985 Aug;26(8):1124-32
pubmed: 4019103
Urol Oncol. 2008 Jan-Feb;26(1):74-85
pubmed: 18190835
J Control Release. 2018 Jun 28;280:87-98
pubmed: 29723616
J Control Release. 2015 Jan 28;198:35-54
pubmed: 25481448
Cancer Cell Int. 2018 Mar 20;18:44
pubmed: 29568237
Sci Rep. 2020 Jun 15;10(1):9648
pubmed: 32541776
J Adv Res. 2018 Jun 25;15:1-18
pubmed: 30581608
J Gastroenterol Hepatol. 2000 Jul;15(7):725-9
pubmed: 10937676
ACS Appl Mater Interfaces. 2020 May 27;12(21):23737-23751
pubmed: 32374147
J Colloid Interface Sci. 2017 Sep 15;502:201-209
pubmed: 28486141
Math Biosci. 2015 Apr;262:105-16
pubmed: 25640871
Nanoscale. 2012 Oct 21;4(20):6289-92
pubmed: 22976154
Biochim Biophys Acta. 1997 Sep 8;1331(2):187-211
pubmed: 9325441
Adv Healthc Mater. 2015 Aug 5;4(11):1681-90
pubmed: 26039933
Adv Drug Deliv Rev. 2009 Jun 21;61(6):428-37
pubmed: 19376175
Colloids Surf B Biointerfaces. 2016 Dec 1;148:157-164
pubmed: 27595890
Cancer Res. 2006 Dec 15;66(24):11851-8
pubmed: 17178882
J Mater Chem B. 2019 Feb 21;7(7):1096-1106
pubmed: 32254777
Pharm Res. 2013 Oct;30(10):2512-22
pubmed: 23314933
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
Nanotechnol Rev. 2018 Feb;7(1):95-122
pubmed: 29404233
ACS Appl Mater Interfaces. 2019 Aug 28;11(34):30610-30620
pubmed: 31359758
J Hepatocell Carcinoma. 2016 Oct 05;3:41-53
pubmed: 27785449
J Control Release. 2012 Jul 20;161(2):175-87
pubmed: 21945285
Adv Drug Deliv Rev. 2017 Jan 1;108:25-38
pubmed: 27137110
Pharmaceutics. 2017 Mar 27;9(2):
pubmed: 28346375
World J Hepatol. 2017 Jul 28;9(21):907-920
pubmed: 28824742
Ther Deliv. 2013 Dec;4(12):1499-510
pubmed: 24304248
J Control Release. 2010 Feb 25;142(1):108-21
pubmed: 19819275
Adv Healthc Mater. 2019 Sep;8(18):e1900612
pubmed: 31389193
Nanoscale. 2019 Nov 28;11(44):21227-21248
pubmed: 31663592
Math Biosci. 2016 Feb;272:6-14
pubmed: 26656677
Angew Chem Int Ed Engl. 2009;48(5):872-97
pubmed: 19142939
Biomaterials. 2008 Oct;29(30):4137-45
pubmed: 18667235
Gastroenterology. 2007 Jun;132(7):2557-76
pubmed: 17570226
J Control Release. 2018 Sep 28;286:358-368
pubmed: 30075210
Biochim Biophys Acta. 2007 Jun;1768(6):1367-77
pubmed: 17400180
J Biomed Mater Res A. 2019 Jul;107(7):1551-1562
pubmed: 30882978
J Carcinog. 2017 May 29;16:1
pubmed: 28694740
Adv Healthc Mater. 2017 May;6(9):
pubmed: 28338285
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
Adv Drug Deliv Rev. 2013 Jan;65(1):36-48
pubmed: 23036225